专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007027661A2 HUMAN G PROTEIN-COUPLED RECEPTOR AND MODULATORS THEREOF FOR THE TREATMENT OF ATHEROSCLEROSIS AND ATHEROSCLEROTIC DISEASE AND FOR THE TREATMENT OF CONDITIONS RELATED TO MCP-1 EXPRESSION 审中-公开
标题翻译：人G蛋白偶联受体及其治疗ATHEROSCLOSOSIS和ATHEROSCLEROTIC DISEASE治疗与MCP-1表达相关的条件的调节剂
公开(公告)号：WO2007027661A2
公开(公告)日：2007-03-08
申请号：PCT/US2006033651
申请日：2006-08-29
申请人： ARENA PHARM INC , HAKAK YARON , UNETT DAVID J , GATLIN JOEL , LIAW CHEN W
发明人： HAKAK YARON , UNETT DAVID J , GATLIN JOEL , LIAW CHEN W
IPC分类号： G01N33/74 , C07K14/72
CPC分类号： G01N33/5041 , A61K38/1709 , A61K49/0008 , C07K14/47 , C07K14/723 , G01N33/6893 , G01N33/74 , G01N2333/726 , G01N2500/00 , G01N2800/32 , G01N2800/323
摘要： The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
摘要翻译：本发明涉及使用G蛋白偶联受体（GPCR）鉴定候选化合物是否是动脉粥样硬化形成的调节剂的方法。在某些实施方案中，GPCR与Gi连接。在某些实施方案中，GPCR是人。本发明的激动剂可用作预防或治疗动脉粥样硬化和动脉粥样硬化疾病（包括冠状动脉疾病，心肌梗死，外周动脉疾病和缺血性中风）的治疗剂。本发明的激动剂另外可用作预防或治疗与MCP-1表达相关的病症的治疗剂，包括但不限于类风湿性关节炎，克罗恩氏病和多发性硬化症。

2. 发明申请

WO2006036688A2 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 审中-公开
标题翻译： GPR43及其调节剂用于治疗与代谢相关的病症
公开(公告)号：WO2006036688A2
公开(公告)日：2006-04-06
申请号：PCT/US2005033795
申请日：2005-09-21
申请人： ARENA PHARM INC , LEONARD JAMES N , HAKAK YARON
发明人： LEONARD JAMES N , HAKAK YARON
CPC分类号： G01N33/566 , G01N33/6845 , G01N2333/726 , G01N2500/00
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.
摘要翻译：本发明涉及通过以下步骤鉴定代谢稳定化合物的方法：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否被调节，其中GPR43功能性的调节指示候选化合物是代谢稳定化的复合。此外，本发明涉及用于鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否增加，其中GPR43功能性的增加指示候选化合物为一种代谢稳定化合物。此外，本发明涉及鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否降低，其中GPR43功能性的降低指示候选化合物为代谢稳定化合物。

3. 发明申请

WO2006036688A9 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 审中-公开
标题翻译： GPR43及其与代谢相关性疾病治疗的调节剂
公开(公告)号：WO2006036688A9
公开(公告)日：2007-05-03
申请号：PCT/US2005033795
申请日：2005-09-21
申请人： ARENA PHARM INC , LEONARD JAMES N , HAKAK YARON
发明人： LEONARD JAMES N , HAKAK YARON
IPC分类号： G01N33/68
CPC分类号： G01N33/566 , G01N33/6845 , G01N2333/726 , G01N2500/00
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.
摘要翻译：本发明涉及通过以下方式鉴定代谢稳定化合物的方法：a）使候选化合物与GPR43接触，和b）确定是否调节GPR43功能性，其中GPR43功能性的调节指示候选化合物是代谢稳定剂复合。此外，本发明涉及用于鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43的功能是否增加，其中GPR43功能的增加指示候选化合物为代谢稳定化合物。此外，本发明涉及用于鉴定代谢稳定化合物的方法，包括：a）使候选化合物与GPR43接触，以及b）确定GPR43的功能性是否降低，其中GPR43功能的降低指示候选化合物为代谢稳定化合物。

4. 发明专利

CA2621144A1 HUMAN G PROTEIN-COUPLED RECEPTOR AND MODULATORS THEREOF FOR THE TREATMENT OF ATHEROSCLEROSIS AND ATHEROSCLEROTIC DISEASE AND FOR THE TREATMENT OF CONDITIONS RELATED TO MCP-1 EXPRESSION 未知
公开(公告)号：CA2621144A1
公开(公告)日：2007-03-08
申请号：CA2621144
申请日：2006-08-29
申请人： ARENA PHARM INC
发明人： UNETT DAVID J , HAKAK YARON , GATLIN JOEL , LIAW CHEN W
IPC分类号： G01N33/74 , C07K14/72
摘要： The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

5. 发明专利

SG155896A1 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 未知
公开(公告)号：SG155896A1
公开(公告)日：2009-10-29
申请号：SG2009059346
申请日：2005-09-21
申请人： ARENA PHARM INC
发明人： LEONARD JAMES N , HAKAK YARON
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.

6. 发明专利

AU2006284926A1 Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression 未知
公开(公告)号：AU2006284926A1
公开(公告)日：2007-03-08
申请号：AU2006284926
申请日：2006-08-29
申请人： ARENA PHARM INC
发明人： GATLIN JOEL , UNETT DAVID J , HAKAK YARON , LIAW CHEN W
IPC分类号： G01N33/74 , C07K14/72
摘要： The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

7. 发明专利

CA2580130A1 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 未知
公开(公告)号：CA2580130A1
公开(公告)日：2006-04-06
申请号：CA2580130
申请日：2005-09-21
申请人： ARENA PHARM INC
发明人： HAKAK YARON , LEONARD JAMES N
IPC分类号： G01N33/68
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.

8. 发明专利

AU2005289810A1 GPR43 and modulators thereof for the treatment of metabolic-related disorders 未知
公开(公告)号：AU2005289810A1
公开(公告)日：2006-04-06
申请号：AU2005289810
申请日：2005-09-21
申请人： ARENA PHARM INC
发明人： HAKAK YARON , LEONARD JAMES N
IPC分类号： G01N33/68
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式